共 50 条
- [21] Trends in demographics and survival for patients (pts) with advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 392S - 392SKubota, K.Masuhara, H.Hosoya, K.Yoh, K.Niho, S.Goto, K.Ohmatsu, H.Nishiwaki, Y.Saijo, N.
- [22] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916Rogado, J.Pacheco-Barcia, V.Fenor De la Maza, M. D.Serra, J. M.Toquero, P.Vera, B.Obispo, B.Mondejar, R.Ballesteros, A.Donnay, O.Colomer, R.Sanchez-Torres, J. M.
- [23] Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung CancerJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1647 - +Reinmuth, NielsReck, Martin
- [24] Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Yamamoto, N.Sato, Y.Tamura, T.Kunitoh, H.Ohe, Y.Katori, N.Sawada, J.Sekine, A.Nakamura, Y.Saijo, N.
- [25] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Hotta, K.Kiura, K.Takigawa, N.Tabata, M.Fujiwara, Y.Tanimoto, M.
- [26] NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSISASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 157 - 157Brahmer, Julie R.Horn, LeoraGandhi, LeenaSpigel, David R.Antonia, Scott J.Rizvi, Naiyer A.Powderly, John D.Heist, Rebecca S.Carvajal, Richard D.Jackman, David M.Sequist, Lecia V.Smith, David C.Leming, Philip D.Topalian, Suzanne L.Hodi, StephenSnzol, MarioHarbison, Christopher T.Kollia, Gerogia D.Gupta, AshokGettinger, Scott N.
- [27] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842SSuk, RPark, SLiu, GCogan-Drew, TZhou, WSu, LLynch, TWain, JChristiani, D
- [28] Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practiceJournal of Cancer Research and Clinical Oncology, 2018, 144 : 2059 - 2066Martin FaehlingBirgit SchwenkSebastian KrambergSabine FallscheerMatthias LeschkeJörn SträterRobert Eckert
- [29] Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practiceJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (10) : 2059 - 2066Faehling, MartinSchwenk, BirgitKramberg, SebastianFallscheer, SabineLeschke, MatthiasStraeter, JoernEckert, Robert
- [30] Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancerNature Medicine, 2022, 28 : 2353 - 2363Justin JeeEmily S. LebowRandy YehJeeban P. DasAzadeh NamakydoustPaul K. PaikJamie E. ChaftGowtham JayakumaranA. Rose BrannonRyma BenayedAhmet ZehirMark DonoghueNikolaus SchultzDebyani ChakravartyRitika KundraRamyasree MadupuriYonina R. Murciano-GoroffHai-Yan TuChong-Rui XuAndrés MartinezClare WilhelmJesse GalleBobby DalyHelena A. YuMichael OffinMatthew D. HellmannPiro LitoKathryn C. ArbourMarjorie G. ZaudererMark G. KrisKenneth K. NgJuliana EngIsabel PreeshagulW. Victoria LaiJohn J. FioreAfsheen IqbalDaniela MolenaGaetano RoccoBernard J. ParkLee P. LimMark LiCandace Tong-LiMadhawa De SilvaDavid L. ChanConnie I. DiakosMalinda ItchinsStephen ClarkeNick PavlakisAdrian LeeNatasha Rekhtman